• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Tocilizumab for treating juvenile idiopathic arthritis
【24h】

Tocilizumab for treating juvenile idiopathic arthritis

机译：托珠单抗治疗青少年特发性关节炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Based on the known relevance of IL-6 in juvenile idiopathic arthritis (JIA) pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA. Tocilizumab is a humanized monoclonal antibody that inhibits signaling through both membrane bound and soluble IL-6R. Areas Covered: The purpose of this article is to summarize the available clinical data on the efficacy and safety of tocilizumab in JIA and to provide our opinion on the place of tocilizumab in current treatment regimens. A literature search for all relevant clinical trials and studies with regards to tocilizumab, JIA and IL-6 was performed through PubMed, in addition to a review of recent conference abstracts. Expert Opinion: Tocilizumab has an important and evolving role in controlling disease activity in patients with JIA. It has proven useful even in patients whose JIA has previously been refractory to other biologic disease modifying anti-rheumatic drugs (DMARDs) and also appears quite effective as monotherapy. Tocilizumab is relatively well tolerated amongst JIA patients, with systemic JIA patients experiencing more serious adverse events overall.
机译：简介：基于IL-6在青少年特发性关节炎（JIA）病理生理学中的已知相关性，托西珠单抗已被研究并批准用于系统性和多关节JIA的治疗。 Tocilizumab是一种人源化单克隆抗体，可通过膜结合和可溶性IL-6R抑制信号传导。涵盖的领域：本文的目的是总结有关托西单抗在JIA中的有效性和安全性的可用临床数据，并就当前治疗方案中托西单抗的位置提供我们的见解。除了对近期会议摘要进行回顾之外，还通过PubMed对与tocilizumab，JIA和IL-6有关的所有相关临床试验和研究进行了文献检索。专家意见：Tocilizumab在控制JIA患者的疾病活动中具有重要且不断发展的作用。事实证明，它对那些JIA以前对其他生物疾病改良抗风湿药（DMARDs）无效的患者也有用，并且作为单一疗法也很有效。在JIA患者中，Tocilizumab的耐受性相对较好，而全身性JIA患者总体上会遇到更严重的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号